Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace Ndeezi

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Plos One|February 24, 2018
Exclusive breastfeeding promotion and neuropsychological outcomes in 5-8 year old children from Uganda and Burkina Faso: Results from the PROMISE EBF cluster randomized trialJames K Tumwine, Victoria Nankabirwa, Hama Abdoulaye Diallo, et al.
Scientific Reports|February 5, 2021
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early lifeNicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, et al.
BMC Pediatrics|March 8, 2025
Immune response and associated factors to Hepatitis B vaccination among children under five attending care at mulago hospitalAndrew Kimera, Joseph Rujumba, Cynthia Kuteesa Ndikuno, et al.
Lancet (London, England)|November 26, 2015
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trialNicolas Nagot, Chipepo Kankasa, James K Tumwine, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Plos One|February 24, 2018
Exclusive breastfeeding promotion and neuropsychological outcomes in 5-8 year old children from Uganda and Burkina Faso: Results from the PROMISE EBF cluster randomized trialJames K Tumwine, Victoria Nankabirwa, Hama Abdoulaye Diallo, et al.
Scientific Reports|February 5, 2021
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early lifeNicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, et al.
BMC Pediatrics|March 8, 2025
Immune response and associated factors to Hepatitis B vaccination among children under five attending care at mulago hospitalAndrew Kimera, Joseph Rujumba, Cynthia Kuteesa Ndikuno, et al.
Lancet (London, England)|November 26, 2015
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trialNicolas Nagot, Chipepo Kankasa, James K Tumwine, et al.
Pageof 14